/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

Virpax Pharmaceuticals Inc share price today is $0.39, up -45.12%. The stock opened at $1.18 against the previous close of $1.22, with an intraday high of $1.18 and low of $0.45.

style

pb-0

Virpax Pharmaceuticals Inc

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$0.39 -0.4512(-45.12%) VRPX at 13 Mar 2026 03:48 PM Biotechnology

Lowest Today 0.45

Highest Today 1.18

Today’s Open 1.18

Prev. Close 1.22

52 Week High 101.33

52 Week Low 0.45

Day’s Range: Low 0.45 High 1.18

52-Week Range: Low 0.45 High 101.33

Virpax Pharmaceuticals Inc Institutional Holdings

Virpax Pharmaceuticals Inc Market Status

Strong Buy: 0

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

Virpax Pharmaceuticals Inc Fundamentals

Market Cap 3.03 M

PB Ratio 0.4844

PE Ratio 0.0

Enterprise Value 0.00 M

Total Assets 1555.61 M

Volume 2782368

Virpax Pharmaceuticals Inc Company Financials

Annual Revenue FY24:null 0.0M, FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M

Annual Profit FY24:null 0.0M, FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M

Annual Net worth FY24:-15189508 -15.2M, FY23:-13614912 -13.6M, FY22:-21456307 -21.5M, FY21:-12148885 -12.1M, FY20:-4487587 -4.5M

Quarterly Revenue Q3/2024:0 0.0M, Q2/2024:0 0.0M, Q1/2024:0 0.0M, Q4/2023:0 0.0M, Q3/2023:0 0.0M

Quarterly Profit Q3/2024:null 0.0M, Q2/2024:null 0.0M, Q1/2024:null 0.0M, Q4/2023:null 0.0M, Q3/2023:null 0.0M

Quarterly Net worth Q3/2024:-2006456 -2.0M, Q2/2024:-3450256 -3.5M, Q1/2024:-3220424 -3.2M, Q4/2023:-4561709 -4.6M, Q3/2023:-5994498 -6.0M

About Virpax Pharmaceuticals Inc & investment objective

Company Information Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also include AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

Organisation Biotechnology

Employees 2

Industry Biotechnology

CEO Mr. Jatinder Dhaliwal

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*